{
  "docId": "019de073-742c-704c-a810-4500da4f1d81",
  "docSlug": "e78883ddf681fdb15564423388c7a078",
  "documentTitle": "Allarity Therapeutics | Investor Conference Presentation Deck | 23 slides",
  "authorId": "allarity-therapeutics",
  "authorName": "Allarity Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 23,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_messages",
  "function": "quantify_opportunity",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "Includes clinical trial references and a stacked bar chart comparing 2019A vs 2026E market size.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-742c-704c-a810-4500da4f1d81/9",
  "deckHref": "/decks/019de073-742c-704c-a810-4500da4f1d81",
  "deckJsonHref": "/decks/019de073-742c-704c-a810-4500da4f1d81.json",
  "deckAnchorHref": "/decks/019de073-742c-704c-a810-4500da4f1d81#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Annual sales in 5 large indications where Dovitinib has shown clinical activity",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4151203c-959b-43d8-9631-dd9d1dd6ad67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Exclusively in-licensed from Novartis. Pan-Tyrosine Kinase Inhibitor (TKI), small molecule, targeted inhibitor of FGFR, VEGFR, and other RTKs. Unique, inhibitory profile. Efficacy demonstrated in monotherapy Phase 3 Renal Cell Carcinoma (mRCC) trial, and in Phase 2 studies spanning 4 additional cancers: gastrointestinal stromal tumors (GIST), liver (HCC), breast, endometrial. Potential tumor vascular normalization that can potentiate delivery and benefit of other anti-cancer agents. DRP® cDx evaluated in 5 different cancers including RCC, GIST, liver, metastatic breast, and endometrial. GMP drug manufacturing contract in place with LONZA. Development strategy potentially similar to Lenvatinib (Lenvima®) by expanding approved mono-therapy indications as well as combo therapy, such as approvals with immune checkpoint inhibitors (e.g. PD-1 inhibitors).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f692a0f-a5a0-48e3-a433-5283386ffd66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1) Source: reported sales (2019A) and eValuatePharma (2026E) 2. NCT01223027 3. NCT01478373 4. NCT01232286 5. NCT01528345 and NCT00958971 6. NCT01379534",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f06aa645-f777-4bbc-9522-bc0c741a8d4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Dovitinib-DRP® Validated in 3rd line mRCC; Broad Combination Therapy Potential",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d8f0a38-9b2f-4c7f-be85-0b2f2191354d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Dovitinib: A Pan-Tyrosine Kinase Inhibitor (TKI)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdd57121-e151-4202-906b-4f86fdfe1015",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "c98ee563-642f-4688-b27e-dceec6ec72ad",
      "evidence": "The slide features a list of bullet points highlighting the benefits and characteristics of Dovitinib, including its inhibitory profile and efficacy in monotherapy.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 5,
      "beatId": "e820002d-ccbd-4705-8e3b-e07f363c4b30",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problem by highlighting the limitations of current cancer treatments and the potential benefits of DRP.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "44643853-e437-4ad1-bf89-99af043fe3be",
      "evidence": "The presentation uses before-after loops to show the potential benefits of DRP in predicting patient response to therapy.",
      "position": 0,
      "objective": "To show the benefits of using DRP for personalized cancer care",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}